Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 16/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23161335 | 0.84 | RIPK1 (0.59) | RIPK1ALDH1A1GAA | |
| SCHEMBL23161075 | 0.83 | RIPK1 (0.57) | RIPK1ALDH1A1 | |
| SCHEMBL9370866 | 0.76 | RIPK1 (0.62) | RIPK1ALDH1A1GAA | |
| SCHEMBL23162681 | 0.76 | ALDH1A1 (0.55) | RIPK1L3MBTL1ALDH1A1 | |
| SCHEMBL19505913 | 0.75 | RIPK1 (0.61) | RIPK1ALDH1A1GAA | |
| SCHEMBL23161321 | 0.74 | RIPK1 (0.62) | RIPK1L3MBTL1ALDH1A1 | |
| SCHEMBL23170601 | 0.73 | RIPK1 (0.41) | RIPK1 | |
| SCHEMBL23170336 | 0.73 | RIPK1 (0.59) | RIPK1ALDH1A1GAA | |
| SCHEMBL22037891 | 0.72 | RIPK1 (0.59) | RIPK1L3MBTL1ALDH1A1 | |
| SCHEMBL24351038 | 0.72 | RIPK1 (0.70) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210094921-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753381-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | RIPK1 1/4885L3MBTL1 2811/4885ALDH1A1 4554/4885 |
| US-20210094921-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | RIPK1 1/4885L3MBTL1 2811/4885ALDH1A1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.